Get all premium features to the best stock analysis tool

Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.

Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated transaction value was $2.8 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $22 million, reflecting both trading and stock price changes.

IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders.  The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.